We’re proud to celebrate a major milestone: over 1,000 corneal treatments successfully performed using theranostics technology with the C4V CHROMO4VIS and RitSight medical devices! These treatments, targeting keratoconus and other corneal pathologies, ...
Regensight is proud to announce that C4V CHROMO4VIS, the first theranostic device in ophthalmology, has officially received CE certification under the Medical Device Regulation (EU) 2017/745 (MDR).This major regulatory achievement confirms the device's c ...
🔬 Breakthrough Advancement in Clinical Research for the Treatment of Keratoconus 🔬 We are excited to announce the publication of the ARGO clinical trial validating theranostics technology for the precision, predictive and personalized treatment of ke ...
Regensight will join the most important and awaited International Annual Conference in corneal and cataract surgery organized by ESCRS in Barcelona (https://congress.escrs.org/) on 6-10 September 2024. With validation of theranostics in the randomized mu ...
We are excited to announce the publication of a new scientific article, entitled "Spatial targeted delivery of riboflavin with a controlled corneal iontophoresis delivery system in theranostic-guided UV-A light photo-therapy", in the prestigious Journal ...
In a recent study published in the prestigious Journal of Cataract & Refractive Surgery, theranostic-guided corneal cross-linking has been confirmed to induce precise and predictive corneal tissue strengthening in eye-bank human donor tissues through ...
